Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.

Cancers (Basel) · 2021 · PMC8201215 · PMID 34204102

hedged sentences

—

closest p

—

boldest claim

The sentences

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (<sup>111</sup>In)/Yttrium 90 (<sup>90</sup>Y) Ibritumomab Tiuxetan (Zevalin<sup>®</sup>) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.

The sentences